Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldstein

Showing results (351-360 of 518) with videos related to

Pageof 52
Sort By:
Journal for Immunotherapy of Cancer|January 12, 2023
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, Keith Dredge, Darryn Bampton, et al.
British Journal of Cancer|September 23, 2016
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancerE Gabriela Chiorean, Daniel D Von Hoff, Josep Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04Samuel Y Ngan, Bryan Burmeister, Richard J Fisher, et al.
Clinical & Experimental Optometry|January 22, 2026
Dose-dependent neurotoxic chemotherapy and corneal nerve morphological changesJeremy Chung Bo Chiang, Dimitra Makrynioti, David Goldstein, et al.
Oncotarget|December 30, 2014
βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancerJoshua A McCarroll, George Sharbeen, Jie Liu, et al.
JAMA Network Open|February 15, 2021
Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral NeuropathyDavid Mizrahi, Susanna B Park, Tiffany Li, et al.
British Journal of Cancer|June 29, 2016
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancerE Gabriela Chiorean, Daniel D Von Hoff, Josep Tabernero, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2010
Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancerHui K Gan, Lori J Bernstein, Jennifer Brown, et al.
Patient Education and Counseling|November 1, 2020
Family communication about genomic sequencing: A qualitative study with cancer patients and relativesAmelia K Smit, Nicci Bartley, Megan C Best, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 30, 2016
Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell CarcinomaAli Hosni, Shao Hui Huang, Wei Xu, et al.
Pageof 52

Showing results (351-360 of 518) with videos related to

Sort By:
Pageof 52
Journal for Immunotherapy of Cancer|January 12, 2023
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, Keith Dredge, Darryn Bampton, et al.
British Journal of Cancer|September 23, 2016
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancerE Gabriela Chiorean, Daniel D Von Hoff, Josep Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04Samuel Y Ngan, Bryan Burmeister, Richard J Fisher, et al.
Clinical & Experimental Optometry|January 22, 2026
Dose-dependent neurotoxic chemotherapy and corneal nerve morphological changesJeremy Chung Bo Chiang, Dimitra Makrynioti, David Goldstein, et al.
Oncotarget|December 30, 2014
βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancerJoshua A McCarroll, George Sharbeen, Jie Liu, et al.
JAMA Network Open|February 15, 2021
Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral NeuropathyDavid Mizrahi, Susanna B Park, Tiffany Li, et al.
British Journal of Cancer|June 29, 2016
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancerE Gabriela Chiorean, Daniel D Von Hoff, Josep Tabernero, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2010
Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancerHui K Gan, Lori J Bernstein, Jennifer Brown, et al.
Patient Education and Counseling|November 1, 2020
Family communication about genomic sequencing: A qualitative study with cancer patients and relativesAmelia K Smit, Nicci Bartley, Megan C Best, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 30, 2016
Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell CarcinomaAli Hosni, Shao Hui Huang, Wei Xu, et al.
Pageof 52